ScholarIQanswers from OpenAlex
Sechenov University
InstitutionResearch output, impact & collaborations
Sechenov University is a institution indexed in ScholarIQ from OpenAlex.
What is known about Sechenov University?
ScholarIQrecord summary
Sechenov University is a research organisation in Moscow, RU. OpenAlex records 41,883 works and 942,153 citations for it. 16,586 researchers list it as their most recent affiliation.
How many works does Sechenov University have?
ScholarIQindexed works
Sechenov University has 41,883 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Sechenov University have?
ScholarIQcitation count
Sechenov University has 942,153 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Sechenov University?
ScholarIQresearcher count
Sechenov University has 16,586 researchers in the ScholarIQ index.
What is the average h-index at Sechenov University?
ScholarIQavg h-index
Sechenov University has an average h-index of 55 in OpenAlex.
What is the ROR of Sechenov University?
ScholarIQror
The ROR for Sechenov University is on the source record.
What is the OpenAlex record for Sechenov University?
ScholarIQopenalex
The OpenAlex for Sechenov University is on the source record.
Who are the most-cited researchers behind Sechenov University?
ScholarIQtop researchers by citations
What are the most-cited papers on Sechenov University?
ScholarIQmost cited works
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Óscar Arrieta, M. Burgio, Jérôme Fayette, H. Lena, Elena Poddubskaya, David E. Gerber, Scott Gettinger, Charles M. Rudin, Naiyer A. Rizvi, Lucio Crinò, George R. Blumenschein, Scott Antonia, Cécile Dorange, Christopher Harbison, F. Graf Finckenstein, Julie R. Brahmer
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis Paz‐Ares, Martin Reck, Christine Baudelet, Christopher Harbison, Brian Lestini, David R. Spigel
Oxidative Damage Is the Earliest Event in Alzheimer Disease
Akihiko Nunomura, George Perry, Gjumrakch Aliev, Keisuke Hirai, Atsushi Takeda, Elizabeth K. Balraj, Paul K. Jones, Hossein Ghanbari, Takafumi Wataya, Shun Shimohama, Shigeru Chiba, Craig Atwood, Robert B. Petersen, Mark A. Smith
EAACI Molecular Allergology User's Guide
Paolo Maria Matricardi, Jörg Kleine‐Tebbe, Hans Jürgen Hoffmann, Rudolf Valenta, Christiane Hilger, Stephanie Hofmaier, Rob C. Aalberse, Ioana Agache, R Asero, Barbara Ballmer‐Weber, Domingo Barber, Kirsten Beyer, Tilo Biedermann, Maria Beatrice Bilò, Simon Blank, Barbara Bohle, Philipp P. Bosshard, Heimo Breiteneder, Helen A. Brough, Luis Caraballo, Jean‐Christoph Caubet, Reto Crameri, Janet M. Davies, Nikolaos Douladiris, Motohiro Ebisawa, Philippe Eigenmann, Montserrat Fernández‐Rivas, Fátima Ferreira, Gabriele Gadermaier, Martin Glatz, Robert G. Hamilton, T. Hawranek, Peter W. Hellings, Karin Hoffmann‐Sommergruber, Thilo Jakob, Uta Jappe, Marek Jutel, Sandip D. Kamath, Edward F. Knol, Peter Korošec, Annette Kuehn, Gideon Lack, Andreas L. Lopata, Mika J. Mäkelä, M. Morisset, Verena Niederberger, Anna Nowak‐Węgrzyn, Nikolaos G. Papadopoulos, Elide A. Pastorello, G. Pauli, Thomas A.E. Platts‐Mills, Daniela Posa, Lars K. Poulsen, Monika Raulf, J. Sastre, Enrico Scala, Johannes Martin Schmid, Peter Schmid‐Grendelmeier, Marianne van Hage, Ronald van Ree, Stefan Vieths, Richard W. Weber, Magnus Wickman, Antonella Muraro, Markus Ollert
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn, David R. Spigel, Everett E. Vokes, Esther Holgado, Neal Ready, Martin Steins, Elena Poddubskaya, Hossein Borghaei, Enriqueta Felip, Luis Paz‐Ares, Adam Płużański, Karen L. Reckamp, Marco Angelo Burgio, Martin Kohlhäeufl, David Waterhouse, Fabrice Barlési, Scott Antonia, Óscar Arrieta, Jérôme Fayette, Lucio Crinò, Naiyer A. Rizvi, Martin Reck, Matthew D. Hellmann, William J. Geese, Ang Li, Anne Blackwood‐Chirchir, Diane Healey, Julie R. Brahmer, Wilfried Eberhardt
How much of the research on Sechenov University is open access?
ScholarIQopen access share
83%OPEN ACCESS